Agilent Technologies, Inc. (A)
| Previous close | 126.03 |
| Open | 125.94 |
| Bid | 126.00 x 1400 |
| Ask | 126.21 x 2200 |
| Day's range | 124.74 - 127.12 |
| 52-week range | 61.13 - 129.34 |
| Volume | 1,758,365 |
| Avg. volume | 1,715,829 |
| Market cap | 38.728B |
| Beta (5Y monthly) | 1.05 |
| PE ratio (TTM) | 54.87 |
| EPS (TTM) | 2.30 |
| Earnings date | 16 Feb 2021 - 22 Feb 2021 |
| Forward dividend & yield | 0.78 (0.61%) |
| Ex-dividend date | 04 Jan 2021 |
| 1y target est | 124.44 |
- Business Wire
Agilent Names Allison Ballmer Senior Vice President of Strategy and Corporate Development
Agilent names Allison Ballmer senior vice president of Strategy and Corporate Development.
- Zacks
Why Is Agilent (A) Up 2.4% Since Last Earnings Report?
Agilent (A) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire
Agilent Receives Approval for GenetiSure Dx Postnatal Assay in Japan
Agilent Technologies Inc. (NYSE: A) announced it has obtained clearance from the Ministry of Health, Labour and Welfare (MHLW) in Japan for the GenetiSure Dx Postnatal Assay – a microarray-based assay for diagnostic use. This assay enables clinical geneticists to detect genetic aberrations associated with developmental delay, intellectual disabilities, congenital anomalies, and unexplained dysmorphic features. The company also announced that it has registered its microarray scanner, SureScan Dx Scanner, as a Class I medical device in Japan, intended for use with the assay.
